



Quest Diagnostics Completes Acquisition of AmeriPath

May 31, 2007

LYNDHURST, N.J., MAY 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced that today it completed its previously announced acquisition of AmeriPath, Inc., a national diagnostic testing company.

"This acquisition creates the world's premier cancer diagnostics company focused on dermatopathology, anatomic pathology and molecular diagnostics," said Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer of Quest Diagnostics. "This combination will accelerate growth, while providing compelling benefits for patients, physicians, hospitals and payers."

About Quest Diagnostics

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: www.questdiagnostics.com.

This communication contains certain forward-looking statements. These forward-looking statements, which may include, but are not limited to, statements concerning the proposed acquisition, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Certain of these risks and uncertainties may include, but are not limited to the risks and uncertainties described in the Quest Diagnostics Incorporated 2006 Form 10-K and subsequent filings.

SOURCE Quest Diagnostics

media, Nancy Fitzsimmons, +1-201-393-5700, or investors, Laure Park, +1-201-393-5030, both of Quest Diagnostics

<http://www.questdiagnostics.com>